Genital Herpes Market Report 2024

The genital herpes market size has grown strongly in recent years. It will grow from $2.05 billion in 2023 to $2.19 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period was driven by heightened awareness and improved diagnosis, advancements in treatment, enhanced healthcare accessibility, public health initiatives, and socio-demographic factors.

The genital herpes market size is expected to see strong growth in the next few years. It will grow to $2.85 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. Anticipated growth in the forecast period is attributed to increasing awareness and educational efforts, advancements in treatment and vaccines, rising incidence rates, adoption of digital health technologies, improved healthcare accessibility, and expanded programs focused on STI awareness. Key trends expected include the uptake of telemedicine, progress in antiviral therapies, ongoing vaccine research and development, broader healthcare access, intensified public awareness campaigns, and the integration of AI and data analytics.

The genital herpes market is poised for growth, driven by increasing attention to sexual health. This focus reflects a growing understanding of its pivotal role in overall well-being and life quality. Sexual health services for genital herpes encompass diagnosis, treatment, counseling, and ongoing management. These services support individuals in managing outbreaks, preventing transmission, and addressing emotional and relationship challenges linked to the condition. Notably, the Local Government Association reported a 33% surge in sexual health consultations in 2022, totaling 4.5 million, along with a 13% increase in diagnostic tests, totaling 2.2 million compared to 2021. Thus, the heightened emphasis on sexual health is expected to boost the genital herpes market.

Major companies in the genital herpes market, are embracing strategic partnerships to bolster their technological capabilities and market presence. These partnerships involve collaborative efforts between organizations to combine resources and expertise toward shared objectives. For instance, in June 2022, Eurocine Vaccines AB entered into a research and collaboration agreement with Redbiotec AG. This partnership grants Eurocine Vaccines exclusive global rights for developing, manufacturing, and commercializing vaccine candidates targeting Herpes Simplex Virus Type 2 (HSV-2), utilizing mRNA- and protein-based technologies. Eurocine Vaccines will manage and finance all activities related to development, manufacturing, and commercialization until a subsequent out-licensing agreement with a third party is secured.

In July 2022, Flerie Invest AB, a Sweden-based investment company specializing in the pharmaceuticals and healthcare sectors, acquired a 15% stake in Eurocine Vaccines AB for an undisclosed sum. This investment is aimed at accelerating the development of medical innovations that address critical patient needs. Flerie Invest intends to support the advancement of Eurocine Vaccines' pipeline of products under development, consistent with its strategy of investing in the biotechnology and life sciences industries. Eurocine Vaccines AB, headquartered in Sweden, focuses on developing therapies and products for the treatment of genital herpes disease.

Major companies operating in the genital herpes market are Pfizer Inc, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, BioNTech SE, Viatris Inc, Teva Pharmaceuticals Inc, Sandoz Inc, Fresenius Kabi AG, Valeant Pharmaceuticals International Inc, Sun Pharmaceutical Industries Ltd, Bausch + Lomb Corporation, Dr Reddy’s Laboratories Ltd, Apotex Inc, Zydus Group, Genocea Biosciences Inc, Glenmark Pharmaceuticals Inc, Maruho Co Ltd, Romark Laboratories, Eurocine Vaccines AB, Vical Incorporated.

North America was the largest region in the genital herpes market in 2023. The regions covered in the genital herpes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the genital herpes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Genital herpes is a sexually transmitted infection (STI) caused primarily by the herpes simplex virus type 2 (HSV-2) or, less commonly, by the herpes simplex virus type 1 (HSV-1). It typically appears as sores or blisters on the genital area, buttocks, or anal region. Transmission occurs through sexual contact with an infected person. Antiviral medications are used to manage symptoms and reduce the risk of transmission to sexual partners.

The diagnosis and treatment of genital herpes involve identifying the infection in patients through methods such as physical examinations, laboratory tests, and reviewing patient history. Treatment methods include oral, injectable, and topical medications, distributed through hospital pharmacies, retail pharmacies, and other channels.

The genital herpes market research report is one of a series of new reports that provides genital herpes market statistics, including genital herpes industry global market size, regional shares, competitors with an genital herpes market share, detailed genital herpes market segments, market trends and opportunities, and any further data you may need to thrive in the genital herpes industry. This genital herpes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The genital herpes market consists of revenues earned by entities by providing services such as diagnostic testing, patient education, counseling, and management of symptoms and outbreaks. The market value includes the value of related goods sold by the service provider or included within the service offering. The genital herpes market also includes sales of antiviral medications, topical treatments, diagnostic test kits, and preventive products such as vaccines. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.